Daytrana: A Long and Winding Road to Approval
The Carlat Psychiatry Report, Volume 4, Number 9, September 2006
https://www.thecarlatreport.com/newsletter-issue/tcprv4n9/
Issue Links: Learning Objectives | Editorial Information
Topics: ADHD
On April 6, 2006, the FDA announced the approval of Daytrana, a transdermal patch version of Ritalin (methylphenidate). While you wouldn’t know it by the gushy promotional copy on Daytrana’s website (www.daytrana.com), the Ritalin patch just barely squeaked through the FDA approval process.
You can't view details of this content, please login or buy subscription here
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.